Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin's lymphoma and chronic lymphocytic...
6 KB (502 words) - 14:22, 26 September 2023
blood cell diseases Metelimumab mab human TGF-β1 systemic scleroderma Milatuzumab mab humanized CD74 multiple myeloma and other hematological malignancies...
135 KB (4,054 words) - 22:35, 2 July 2024
anti-CD20 monoclonal antibody for treatment of cancer.[citation needed] Milatuzumab (IMMU-110) is an anti-CD74 monoclonal antibody for autoimmune diseases...
5 KB (401 words) - 18:44, 18 June 2024
on a number of cancer cell types. Possible cancer therapy target. See milatuzumab. Autoantibodies against CD74 have been identified as promising biomarkers...
19 KB (2,221 words) - 01:42, 3 December 2023
mikamycin (INN) milacainide (INN) milacemide (INN) milameline (INN) milatuzumab (USAN) milenperone (INN) mildronate milfasartan (INN) milipertine (INN)...
9 KB (425 words) - 22:18, 23 March 2024
December 2011[update], it is undergoing Phase I/II clinical trials. When used with milatuzumab it showed activity. This drug was developed by Immunomedics, Inc. and...
4 KB (283 words) - 14:19, 26 September 2023
vedotin§ Lintuzumab§ Lorvotuzumab mertansine§ Lumretuzumab§ Matuzumab§ Milatuzumab§ Naxitamab Nimotuzumab† Obinutuzumab Ocaratuzumab§ Otlertuzumab§ Onartuzumab§...
5 KB (368 words) - 22:00, 19 October 2020
vedotin§ Lintuzumab§ Lorvotuzumab mertansine§ Lumretuzumab§ Matuzumab§ Milatuzumab§ Naxitamab Nimotuzumab† Obinutuzumab Ocaratuzumab§ Otlertuzumab§ Onartuzumab§...
4 KB (241 words) - 11:41, 22 April 2022
vedotin§ Lintuzumab§ Lorvotuzumab mertansine§ Lumretuzumab§ Matuzumab§ Milatuzumab§ Naxitamab Nimotuzumab† Obinutuzumab Ocaratuzumab§ Otlertuzumab§ Onartuzumab§...
3 KB (129 words) - 01:04, 19 July 2023